Centogene Temettü

Temettü kriter kontrolleri 0/6

Centogene şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-1.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-1.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Aug 06

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CNTG.F şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CNTG.F şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Centogene Piyasaya Karşı Temettü Getirisi

CNTG.F temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CNTG.F)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Healthcare)	1.7%
Analist tahmini (CNTG.F) (3 yıla kadar)	n/a

Önemli Temettü: CNTG.F şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CNTG.F şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CNTG.F şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CNTG.F herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Centogene Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer

Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD)

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Consensus forecasts updated

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020)

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene reports Q1 results

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Consensus forecasts updated

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)

Consensus revenue estimates increase to €137.5m

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study